Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and ...

Soft earnings didn't appear to concern Bio-Techne Corporation's ( NASDAQ:TECH ) shareholders over the last week. We ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a ...

Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...

Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results this Wednesday before market open. Here’s ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section Technologies support spatial multiomic analysis and deeper insights for pathology ...

Shares of Bio-Techne Corp. TECH slid 4.09% to $65.86 Thursday, on what proved to be an all-around grim trading session for ...